Specification
Description
Orelabrutinib, also known as ICP-022, is a potent, orally active, and irreversible Bruton's tyrosine kinase (BTK) inhibitor, being developed by InnoCare Pharma, for the treatment of chronic lymphocytic leukaemia.
Synonyms
Orelabrutinib; ICP-022; ICP022; ICP 022
IUPAC Name
2-(4-phenoxyphenyl)-6-[1-(prop-2-enoyl)piperidin-
4-yl]pyridine-3-carboxamide
Canonical SMILES
O=C(C1=CC=C(C2CCN(C(C=C)=O)CC2)N=C1C3=CC=C(OC4=CC=CC=C4)C=C3)N
InChI
InChI=1S/C26H25N3O3/c1-2-24(30)29-16-14-18(15-17-29)23-13-12-22(26(27)31)25(28-23)19-8-10-21(11-9-19)32-20-6-4-3-5-7-20/h2-13,18H,1,14-17H2,(H2,27,31)
InChI Key
MZPVEMOYADUARK-UHFFFAOYSA-N
Solubility
Soluble in DMSO
Shelf Life
>3 years if stored properly
Storage
Dry, dark and at 0-4 °C for short term (days to weeks) or -20 °C for long term (months to years).
Drug Formulation
This drug may be formulated in DMSO
Elemental Analysis
C, 73.05; H, 5.89; N, 9.83; O, 11.23
HS Tariff Code
2934.99.9001
Shipping
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Stock Solution Storage
0-4 °C for short term (days to weeks), or -20 °C for long term (months).